Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.39 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | ADH1B | P00325 | 1/20 | 0.32 |
| ▸ | ADH1C | P00326 | 1/20 | 0.32 |
| ▸ | ADH1A | P07327 | 1/20 | 0.32 |
| ▸ | ADH4 | P08319 | 1/20 | 0.32 |
| ▸ | ADH7 | P40394 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL489761 | 0.89 | ALDH1A1 (0.39) | ALDH1A1CYSLTR2CYSLTR1PPARGKDM4E | |
| SCHEMBL489432 | 0.89 | ALDH1A1 (0.39) | ALDH1A1CYSLTR2CYSLTR1PPARGKDM4E | |
| SCHEMBL489247 | 0.87 | ALDH1A1 (0.36) | ALDH1A1CYSLTR2CYSLTR1PPARGKDM4E | |
| SCHEMBL1332960 | 0.85 | CYSLTR2 (0.45) | ALDH1A1CYSLTR2CYSLTR1PPARGKMT2A | |
| SCHEMBL6882280 | 0.82 | CYSLTR2 (0.43) | ALDH1A1CYSLTR2CYSLTR1PPARG | |
| SCHEMBL9857565 | 0.79 | CYSLTR2 (0.40) | CYSLTR2CYSLTR1PPARGKMT2APRSS1 | |
| SCHEMBL1880780 | 0.79 | CYSLTR2 (0.40) | ALDH1A1CYSLTR2CYSLTR1KMT2A | |
| SCHEMBL489388 | 0.79 | KMT2A (0.43) | ALDH1A1CYSLTR2CYSLTR1PPARGKDM4E | |
| SCHEMBL6683043 | 0.78 | ADH1B (0.39) | ALDH1A1CYSLTR2CYSLTR1PPARGKMT2A | |
| SCHEMBL1856281 | 0.76 | CYSLTR2 (0.38) | CYSLTR2CYSLTR1PPARGKMT2APRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1515723-B1 | SUBSTITUTED DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | VITTAL MALLYA SCIENT RES FOUNDATION (IN) | 2014-02-12 | — | — | EP | disclosed |
| US-8106062-B1 | Calcium channel blockers | DIAKRON PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-7687511-B2 | Substituted dihydropyrimidines, dihydropyrimidones and dihydropyrimidinethiones as calcium channel blockers | PULLELA PHANI KUMAR | 2010-03-30 | — | — | US | disclosed |
| US-20080125449-A1 | SUBSTITUTED DIHYDROPYRIMIDINES, DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | PULLELA PHANI KUMAR | 2008-05-29 | — | — | US | disclosed |
| EP-1542683-A2 | CALCIUM CHANNEL BLOCKERS | Diakron Pharmaceuticals, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-1515723-A2 | SUBSTITUTED DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2005-03-23 | — | — | EP | disclosed |
| WO-2004024153-A2 | CALCIUM CHANNEL BLOCKERS | DIAKRON PHARMACEUTICALS, INC. (US) | 2004-03-25 | — | — | WO | disclosed |
| US-20040058942-A1 | Substituted dihydropyrimidines, dihydropyrimidones and dihydropyrimidinethiones as calcuim channel blockers | PULLELA PHANI KUMAR (US) | 2004-03-25 | — | — | US | disclosed |
| WO-2003105854-A2 | SUBSTITUTED DIHYDROPYRIMIDINES, DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125449-A1 | SUBSTITUTED DIHYDROPYRIMIDINES, DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | ORAI1, RYR2, RYR1 | ALDH1A1 1580/4885CYSLTR2 608/4885CYSLTR1 672/4885 |
| US-20040058942-A1 | Substituted dihydropyrimidines, dihydropyrimidones and dihydropyrimidinethiones as calcuim channel blockers | ORAI1, CACNA1B, CACNA1I | ALDH1A1 1674/4885CYSLTR2 614/4885CYSLTR1 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.